NCT02176031View on ClinicalTrials.gov

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Graft Versus Host Disease
Interventions
DRUG

Natalizumab

DRUG

Methylprednisolone

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02176031 - Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD | Biotech Hunter | Biotech Hunter